{"id":11731,"date":"2003-10-01T11:31:05","date_gmt":"2003-10-01T11:31:05","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=11731"},"modified":"2014-05-27T11:06:21","modified_gmt":"2014-05-27T11:06:21","slug":"time-on-anti-hiv-therapy-is-a-protective-factor-for-liver-fibrosis-in-hiv-hcv-coinfected-patients","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/11731","title":{"rendered":"Time on anti-HIV therapy is a protective factor for liver fibrosis in HIV-HCV coinfected patients"},"content":{"rendered":"<p><strong>To assess the factors associated with liver fibrosis in HIV and hepatitis C virus (HIV\/HCV) coinfected patients eligible for anti-HCV therapy, researchers performed an observational, single centre, cross-sectional study of 180 HIV\/HCV coinfected patients who underwent liver biopsy between May 1998 and November 2001.<\/strong><\/p>\n<p>A total of 126 patients with a known date of HCV infection were evaluated. Liver fibrosis was defined as a Knodell stage of fibrosis 1-4.<\/p>\n<p>The mean age was 36.7 (3.8) years, 81% were male and had a mean age of 20.5 (3.8) years at HCV infection. Mean CD4 cell count and plasma HIV-1 RNA load at the time of biopsy were 552 cell\/mm3 (239) and 2.5 log10 (0.9), respectively.<\/p>\n<p>One hundred and eighteen patients had been on antiretroviral therapy (ART) for a median of 45 months (Q1-Q3: 21-75) and 84 on protease inhibitor for a median of 12.0 months (Q1-Q3: 0-29.5); 55 had an AIDS event or a CD4 cell count nadir &lt; 200 cells\/mm3 prior to biopsy.<\/p>\n<p>Median histological activity index was 6 and 27% had a Knodell stage of fibrosis 0. On the multivariate analysis time on ART, CD4 cell count at the time of liver biopsy, age at HCV infection acquisition and alcohol intake (&gt; 50 g\/day) were associated with liver fibrosis.<\/p>\n<p>The authors conclude: \u201cART should be a priority in HIV-HCV coinfected patients eligible for anti-HCV treatment as it is a protective factor for liver fibrosis.\u201d<\/p>\n<p>Source: HIVandHepatitis.com<br \/>\n<a href=\"http:\/\/www.hivandhepatitis.com\/hiv_hcv_co_inf\/081503a.html\">http:\/\/www.hivandhepatitis.com\/hiv_hcv_co_inf\/081503a.html<\/a><\/p>\n<p>Reference:<\/p>\n<p>Tural C and others. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. Journal of Viral Hepatitis 10(2): 118-125. March 2003.<\/p>\n<p>\u00a9 Copyright 2002 by HIV and Hepatitis.com. All Rights Reserved. Reproduction for personal or educational use is encouraged and does not require permission. Written permission is required to re-print copyrighted articles but is almost always granted (email <a href=\"mailto:publisher@HIVandHepatitis.com\">publisher@HIVandHepatitis.com<\/a>).<\/p>\n<h3>Comment<\/h3>\n<p><strong>One hypothesis would be that antiretroviral therapy improves immune function and enables the body to control HCV better, achieving a situation similar to monoinfected patients.<\/strong><\/p>\n<p><strong>This may slow down the fibrosis rate, as coinfected patients otherwise show a more rapid progression of fibrosis. This study confirms earlier data from Benhamou published in Hepatology in 2000.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>To assess the factors associated with liver fibrosis in HIV and hepatitis C virus (HIV\/HCV) coinfected patients eligible for anti-HCV therapy, researchers performed an observational, single centre, cross-sectional study of 180 HIV\/HCV coinfected patients who underwent liver biopsy between May &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-11731","post","type-post","status-publish","format-standard","hentry","category-hepatitis-coinfection"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/11731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=11731"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/11731\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=11731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=11731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=11731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}